Work

High Response Rate To Combination Lenalidomide-Rituximab In FcγRIIIa-F Carriers With Indolent Or Mantle Cell Lymphomas Previously Refractory To Rituximab

FWCI: 0.223
Cites:
Cited by: 1
Related to: 10